



National Influenza Vaccine Summit

CSL Biotherapies Update

Paul R. Perreault

President, CSL Biotherapies Inc.

May 17, 2010 - Phoenix (Arizona)

CSL Biotherapies

2009 Pandemic Influenza

- First H1N1 vaccine trial in the world
- First to demonstrate that 1 dose of H1N1 Vaccine sufficient to provide protection in adults, N.E.J.M Sept.10, 2009
- H1N1 Vaccine provided to
 - US
 - Australia
 - Singapore
 - Germany
 - Canada
 - WHO



THE NEW ENGLAND JOURNAL OF MEDICINE

ORIGINAL ARTICLE

Response after One Dose of a Monovalent Influenza A (H1N1) 2009 Vaccine — Preliminary Report

Michael J. Gensberg, M.D., M.P.H., Michaela L. Smith, D., M.D., M.A.H.I.D.,
Gordon F. Hargrett, M.D., Ph.D., Christine H. Wu, M.D.,
Chunmei Gifford, R.N., M.B., B.S., Julia B. Smith, M.D., M.P.H.,
Gail Davidson, R.Pharm., William M. D., M.B.A., Corinne Leggett, R.N.,
Shawn Worthington, M.D., and Russell J. Baker, M.B., B.S., M.D., F.R.A.C.P.

20-May-10

CSL Biotherapies

Seasonal influenza

- NH 2009-10 seasonal flu vaccine

- No delay in delivery

- 8 Million doses

- Pediatric indication : ≥ 6 Mo.

- Fast filling syringe line on US soil

- Merck & Co

- Broader US patient access to Afluria®

- Strong Partnership history

- Gardasil®

- CSL distribute Merck's Vaccines in Australia



CSL Biotherapies